• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
Share
Announcements, ProteaseTag®

ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health

October 27, 2017
-
Posted by Webmaster

ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s ProteaseTag® point-of-care technology for real-time management of small airway inflammation in a spectrum of respiratory diseases including Cystic Fibrosis and COPD. ProAxsis’ technology will allow clinicians to measure active Neutrophil Elastase as a potential predictor of chronic respiratory disease exacerbations and severity in COPD and cystic fibrosis, and offers a potential companion diagnostic for disease modifying agents. COPD affects more than 24 million Americans, and is the third leading cause of death. National Jewish Health is the #1 ranked Hospital in Respiratory Disease by US News and World Report 2017.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “National Jewish Health is a globally recognised leader in respiratory care and research, so this agreement brings tremendous resources and expertise to our effort to bring the ProteaseTag® technology to market in the US.”

Any queries concerning ProAxsis’ Immunoassay for measuring active neutrophil elastase, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

October 27, 2017

Related News

Other posts that you should not miss.
Announcements, News

ProAxsis appoints experienced Sales and Marketing Manager

April 20, 2016
-
Posted by Webmaster

ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales …

Read More
April 20, 2016
Posted by Webmaster
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the …

Read More
June 19, 2017
Posted by Webmaster
Announcements, News

ProAxsis wins Innovative Business of the Year Award

June 4, 2018
-
Posted by David Ribeiro

ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First …

Read More
June 4, 2018
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
NEXT POST →
ProAxsis appoints first distributor for NE Immunoassay
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health - ProAxsis